Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics
Status:
Withdrawn
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a pivotal trial that will examine therapeutic equivalence (BE) of a new generic
fixed-dose combination product containing fluticasone propionate 100 mcg / salmeterol 50 mcg
(as xinafoate salt) and reference listed drug (RLD) Advair® Diskus 100/50 in adult patients
with chronic but stable asthma as defined in the National Asthma Education and Prevention
Program Expert Panel Report 3 (NAEPP 3) guidelines
Phase:
Phase 3
Details
Lead Sponsor:
Actavis Inc.
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Salmeterol Xinafoate Xhance